Prostate Health Index in a sample of Iraqi patients with Prostate Cancer and Benign Prostatic Hyperplasia

There is widespread of PSA using as a Prostate Cancer biomarker (threshold of 4ng/ml),but there is no single PSA value that avoids missing serious cancers at a treatable phase, avoids false-positives and unnecessary prostate biopsies.The evaluation of the clinical significant of[-2]proPSA and the Prostate Health Index(PHI) in diagnosis of Prostate Cancer was done in this research to enhance the correct prediction of the prostate cancer.The aim, of this study is to improve the method of testing by using newer PSA biomarkers in the subject sera for evaluating the diagnostic significance of[-2]proPSA and Prostate Health Index(PHI)in the detect of prostate cancer in early stages.A case-control researchcomprising54 patients over 50 years old age having Prostate Cancer and Benign Prostatic Hyperplasia recruited from Iraqi urological clinics unit and AL-Amal National Hospital for Cancer Management during the period from July 2018 to March 2019. There was a significantly high difference (P<0.001) ofserumPSA,P2PSA and PHI levels among all the study groups. The cut-off values of[-2]proPSA and Prostate Health Index (PHI)based on the ROC curve results in current study were >322 pg/ml and >578 respectively for Prostate cancer patients , while their values range between 322-89 pg/ml,and 578-209 respectively for BPH patients,and<89 pg/ml and<209for apparently healthy men respectively, the area under curve(AUC)of(P2PSAg)and PHI were0.968,0.960 for PCa group against noncancerous group respectively,0.85 and 0.796 for BPH group against control group respectively. Their levels show significant increase in PCa patients in comparison with noncancerous group and in BPH patients when compared with control group.